A sweeping review of clinical trials finds little strong evidence that medicinal cannabinoids reliably treat depression, anxiety, PTSD or most substance-use disorders, and it flags higher rates of adverse effects and patchy study quality that call routine prescribing into question.
A team at the University of Sydney examined 54 randomized controlled trials spanning from 1980 to 2025, focusing on cannabis compounds used as primary treatments. The pooled sample totaled 2,477 people, mostly men with an average age of about 33, and the findings landed in Lancet Psychiatry. The headline is blunt: the data rarely supports prescribing cannabinoids for common mental health conditions.
The analysis found no meaningful benefit for anxiety disorders, psychotic disorders, PTSD, opioid use disorder or anorexia nervosa, and depression trials simply didn’t meet the review’s criteria. A handful of outcomes showed tentative improvement — for cannabis use disorder, insomnia, some Tourette’s symptoms and autistic traits — but those results were low quality and inconsistent. Overall, the paper concluded that cannabis-based treatments are “rarely justified” for routine use in these domains.
Worryingly, the review reports a roughly 75 percent increase in adverse side effects among patients taking cannabinoids versus controls in these trials. That risk bump, combined with uneven trial methods and variable product types, makes it hard to claim clear clinical advantage. The studies mixed different doses, formulations and follow-up lengths, so any small positive signals are difficult to interpret with confidence.
The authors also flagged critical evidence gaps: there were not enough trials to draw conclusions about ADHD, bipolar disorder, OCD or tobacco use disorder, and no randomized trials for depression met their standards. Those absences matter because clinicians and patients are already using cannabis-derived products to try to manage emotional and behavioral problems without robust trial backing. The review therefore questions approvals and routine prescribing for those indications.
“Though our paper didn’t specifically look at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes — for example, a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments,” the lead author warned. That point cuts to the clinical trade-off: if a cheap or easy option delays access to proven therapies, overall outcomes could worsen even when short-term relief seems present.
Independent experts urged caution but acknowledged legitimate medical uses for cannabis-based medicines in other conditions. “This new review is the most comprehensive attempt to date to evaluate cannabis specifically for anxiety, depression and PTSD.” Another expert added that while cannabis has bona fide roles in reducing seizures, easing multiple sclerosis symptoms and treating certain kinds of pain, mental health care is not necessarily among them at this time.
Clinicians also highlighted practical concerns about real-world use versus trial conditions. “Clinical trial conditions differ from real‑world use, where people often consume higher doses, with more frequency, and sometimes alongside alcohol or nicotine,” a psychiatrist noted. People who self-medicate may escalate doses, rely on cannabis to cope with stress, or mask symptoms that would respond to therapy or medication with stronger evidence behind them.
Experts encourage users and clinicians to watch for warning signs and to keep mental health care priorities clear. “Using cannabis to manage emotional distress may delay access to proven treatments,” one clinician cautioned. Patients should track mood, sleep, concentration and social engagement, look out for tolerance or increasing paranoia, and seek professional support if functioning declines rather than treating complex problems with an under-evidenced product.
